Funding roundup: Raptor, Conatus, Silence, Northwest, Trinity, Egalet
Rare disease play Raptor Pharmaceutical Corp. (NASDAQ:RPTP) raised $85.5 million through the sale of 9.5 million shares at $9 in a follow-on underwritten by Citigroup; Leerink; Cowen; JMP Securities; and Janney Montgomery Scott. The company proposed the offering post-market on Monday when its shares were valued at $12.04. Raptor rose $0.50 to $10.48 on Thursday.
Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) raised $20.1 million through the sale of 3.5 million shares at $5.75 in a follow-on underwritten by Stifel and Roth Capital Partners. The company proposed the offering after market Wednesday when its shares closed at $6.81. Conatus lost $0.68 to $6.13 on Thursday. Last week, Conatus said pan-caspase inhibitor emricasan met the primary endpoint in a Phase II trial to treat non-alcoholic fatty liver disease (NAFLD) (see BioCentury Extra, March 26). ...